41 – 50 of 96
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
High amplified in breast cancer 1 is a significant predictor of improved response to adjuvant tamoxifen in premenopausal women
2008) 31st Annual San Antonio Breast Cancer Symposium(
- Contribution to conference › Abstract
- 2007
-
Mark
In-Source Decay Causes Artifacts in SELDI-TOF MS Spectra.
(
- Contribution to journal › Article
-
Mark
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
(
- Contribution to journal › Article
- 2005
-
Mark
Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
(
- Contribution to journal › Article
- 2004
-
Mark
Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations.
(
- Contribution to journal › Article
- 2003
-
Mark
Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer
(
- Contribution to journal › Article
-
Mark
Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence.
(
- Contribution to journal › Article
-
Mark
Are cellular polarisation and mitotic frequency prognostic factors for local recurrence in patients with ductal carcinoma in situ of the breast?
(
- Contribution to journal › Article
-
Mark
Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer
(
- Contribution to journal › Article